Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 8/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 8/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17456064 | 0.83 | RBP4 (0.47) | NAMPTRBP4SCD | |
| SCHEMBL17455922 | 0.83 | ALDH1A1 (0.43) | RBP4SCDKDM4EALDH1A1 | |
| SCHEMBL17456003 | 0.83 | RBP4 (0.41) | RBP4SCDKDM4EALDH1A1 | |
| SCHEMBL17455927 | 0.81 | RBP4 (0.53) | RBP4ALDH1A1 | |
| SCHEMBL17455982 | 0.81 | HPGD (0.51) | NAMPTRBP4ALDH1A1HSD17B10 | |
| SCHEMBL17456018 | 0.81 | CYP11B1 (0.42) | RBP4 | |
| SCHEMBL17455956 | 0.81 | TMEM97 (0.51) | NAMPTRBP4ALDH1A1 | |
| SCHEMBL17456006 | 0.79 | NAMPT (0.46) | NAMPTRBP4 | |
| SCHEMBL21238936 | 0.78 | RBP4 (0.40) | RBP4SCDKDM4EALDH1A1 | |
| SCHEMBL17456067 | 0.77 | NAMPT (0.48) | NAMPTRBP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982666-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2982666-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-9598398-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| EP-2982666-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-10 | — | — | EP | disclosed |
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | PSEN1, PSEN2, BACE1 | NAMPT 367/4885RBP4 4341/4885SCD 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.